Skip to Main Content Skip to Site Map Skip to Accessibility Statement

Recommend Technology Appraisals

Service notifications for recommended Technology Appraisals (TAs)

Technology Appraisals are listed below in alphanumerical order with links to further information on the NICE website.

TitleDescriptionDate addedDownload
TA755

Overview | Risdiplam for treating spinal muscular atrophy | Guidance | NICE

20-02-2024 DownloadPreview
TA934

Overview | Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms | Guidance | NICE

20-02-2024 DownloadPreview
TA929

Overview | Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | Guidance | NICE

20-02-2024 DownloadPreview
TA729(EXTENSION TO NICE TA729)

Overview | Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | Guidance | NICE

02-02-2024 DownloadPreview
TA919

Overview | Rimegepant for treating migraine | Guidance | NICE

16-01-2024 DownloadPreview
TA925

Overview | Mirikizumab for treating moderately to severely active ulcerative colitis | Guidance | NICE

16-01-2024 DownloadPreview
TA939

Overview | Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | Guidance | NICE

16-01-2024 DownloadPreview
TA935

Overview | Secukinumab for treating moderate to severe hidradenitis suppurativa | Guidance | NICE

05-01-2024 DownloadPreview
TA931

Overview | Zanubrutinib for treating chronic lymphocytic leukaemia | Guidance | NICE

05-01-2024 DownloadPreview
TA921 (Review of TA356)

Overview | Ruxolitinib for treating polycythaemia vera | Guidance | NICE

05-01-2024 DownloadPreview
TA920

Overview | Tofacitinib for treating active ankylosing spondylitis | Guidance | NICE

05-01-2024 DownloadPreview
TA927

Overview | Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | Guidance | NICE

05-01-2024 DownloadPreview
TA916

Overview | Bimekizumab for treating active psoriatic arthritis | Guidance | NICE

05-01-2024 DownloadPreview
TA915

Overview | Pegunigalsidase alfa for treating Fabry disease | Guidance | NICE

05-01-2024 DownloadPreview
TA917

Overview | Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | Guidance | NICE

05-01-2024 DownloadPreview
TA914

Overview | Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | Guidance | NICE

05-01-2024 DownloadPreview
TA918

Overview | Bimekizumab for treating axial spondyloarthritis | Guidance | NICE

05-01-2024 DownloadPreview
TA912

Cipaglucosidase Alfa with Miglustat for treating Late-Onset Pompe Disease

21-12-2023 DownloadPreview
TA888

Risankizumab For Previously Treated Moderately To Severely Active Crohn’s Disease

04-12-2023 DownloadPreview
TA902

Dapagliflozin For Treating Chronic Heart Failure With Preserved Or Mildly Reduced Ejection Fraction

04-12-2023 DownloadPreview
1 2 3 22

 

NICE Ref Title Date Issued by HSCB
TA234 Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor 05/01/2012
TA233 Golimumab for the treatment of ankylosing spondylitis 20/02/2012
TA232 Retigabine for the adjunctive treatment of partial onset seizures in epilepsy 05/01/2012
TA230 Bivalirudin for the treatment of ST-segment-elevation myocardial infarction 05/01/2012
TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion 05/01/2012
TA228 Bortezomib and thalidomide for the firstline treatment of multiple myeloma 05/01/2012
TA227 Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer 05/01/2012
TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma 05/01/2012
TA225 Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti- rheumatic drugs 20/02/2012
TA223 Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease 05/01/2012
TA222 Trabectedin for the treatment of relapsed ovarian cancer 05/01/2012
TA221 Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura 05/01/2012
TA220 Golimumab for the treatment of psoriatic arthritis 20/02/2012
TA216 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia 05/01/2012
TA215 Pazopanib for the first-line treatment of advanced renal cell carcinoma 05/01/2012
TA208 Trastuzumab for the treatment of HER2-positive metastatic gastric cancer 05/01/2012
TA203 Liraglutide for the treatment of type 2 diabetes mellitus 20/02/2012
TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C 05/01/2012
TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis 20/02/2012
TA198 Tocilizumab for the treatment of rheumatoid arthritis 05/01/2012
TA197 Dronedarone for the treatment of non-permanent atrial fibrillation 20/02/2012
TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor 05/01/2012
TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia 05/01/2012
TA190 Pemetrexed for the maintenance treatment of non-small-cell lung cancer 05/01/2012
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children 05/01/2012
TA187 Infliximab (review) and adalimumab for the treatment of Crohn’s disease 05/01/2012
TA186 Certolizumab pegol for the treatment of rheumatoid arthritis 20/02/2012
TA169 Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma 05/01/2012
TA166 Cochlear implants for children and adults with severe to profound deafness 05/01/2012
TA98 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents 14/09/2016
TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C 05/01/2012
TA23 Temozolomide for the treatment of recurrent malignant gliomaC 02/08/2016
TA20 Riluzole for the treatment of Motor Neurone Disease 01/08/2016